Bioidentical

Retracted: highly cited paper

From The New York Times, May 6, 2010
U.S. Panel Criticized as Overstating Cancer Risks
by Denise Grady

from The New York Times, May 5, 2010
New Alarm Bells About Chemicals and Cancer
Nicholas D. Kristof

From The New York Times Magazine, April 12, 1020
The Estrogen Dilemma
by Cynthia Gorney

Obama should have second thoughts about deals with drug companies
By Erika Schwartz, MD, Kent Holtorf MD and David Brownstein MD

The summer recess is allowing Congress to gauge first-hand the public’s rising concern for the cost and substance of the proposed healthcare reform. The concern, however, does not seem to be shared in Washington by the Administration and its new fast friends – the drug companies.

The American Medical Association has shown where its loyalties lie – and it’s not with America’s doctors or their patients.

Instead the AMA has demonstrated yet again it is bought-and-paid-for tool of the pharmaceutical industry.

At its annual meeting in Chicago this week, the AMA decided there is “evidence” that long-term use of Human Growth Hormone can present more risks than benefits and that bioidentical hormones are no safer than traditional estrogen and progesterone products.

Well, thanks for the warning guys.

The AMA doesn't represent doctors, or their patients' best interests

The American Medical Association has shown where its loyalties lie – and it’s not with America’s doctors or their patients.

Instead the AMA has demonstrated yet again it is a bought-and-paid-for tool of the pharmaceutical industry.

At its annual meeting in Chicago this week, the AMA decided there is “evidence” that long-term use of Human Growth Hormone can present more risks than benefits and that bioidentical hormones are no safer than traditional estrogen and progesterone products.

Find out here what interests you and have your say. We look forward to your feedback, interests, and suggestions